Mogrify
Transforming the development of life saving cell therapies via the licence of proprietary cell conversions tailored to any therapeutic application.
| GBP | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (12 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | (2830 %) | (3066 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | (2554 %) | (2882 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Mogrify operates in the biotechnology sector, focusing on the development of ex vivo cell therapies and pioneering in vivo reprogramming therapies. The company has developed a proprietary platform that leverages transcriptomic and epigenetic data to identify optimal combinations of transcription factors for converting any cell type into another. This technology is aimed at addressing diseases with high unmet clinical needs by enabling scalable and efficient cell conversions. Mogrify serves pharmaceutical companies, research institutions, and healthcare providers, offering solutions that enhance the development and maintenance of cell therapies. The business model is based on licensing its technology, forming strategic partnerships, and executing royalty-bearing deals. Revenue is generated through upfront payments, milestone payments, and royalties from commercialized therapies.
Keywords: biotechnology, cell therapy, reprogramming, transcriptomic data, epigenetic data, transcription factors, scalable solutions, pharmaceutical partnerships, healthcare innovation, royalty deals.